Acute Ischemic Stroke- Pipeline Insight, 2025

This “Acute Ischemic Stroke- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Acute Ischemic Stroke: Understanding

Acute Ischemic Stroke: Overview

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7, 00,000 people each year. Acute ischemic stroke is sometimes preceded by a transient ischemic attack (TIA), which is a temporary episode of brain dysfunction due to decreased blood flow Acute ischemic stroke is due to blockage of the large blood vessels in the brain may be treated with mechanical removal of the blood clot in the vessel (mechanical thrombectomy) up to 24 hours after onset of stroke symptoms. Symptoms depend on severity of the stroke and location in the brain. Common stroke signs and symptoms include the following abrupt onset of hemiparesis, monoparesis, or (rarely) quadriparesis, hemisensory deficits, monocular or binocular visual loss, visual field deficits, diplopia, dysarthria and facial droop. Ischemic strokes can be caused by a blockage anywhere along the arteries feeding the brain. The blockages can occur for a variety of reasons, including the build-up of fatty material (atheroma) along the walls of an artery, which reduces blood flow. Breaking off of atheroma from the artery wall. The material can flow with the blood and become lodged in a smaller artery, causing a blockage and inflammation or an infection that narrows blood vessels that lead to the brain.

The pathophysiology of AIS is both simple and complex. Simple in that the initiating event is the occlusion of an intracranial or neck blood vessel that in most cases impairs blood flow to a portion of the brain, leading to infarction of brain tissue in the part of the brain supplied by that blood vessel. The vessel occlusion can occur in relationship to a local vessel occlusion typically in patients with intracranial atherosclerosis, artery to artery embolization typically from an internal carotid artery (ICA) plaque, or secondary to embolization of a clot from the heart to a brain vessel as exemplified by atrial fibrillation. The process of ischemic brain injury is complex because many different cellular consequences occur when cerebral blood flow (CBF) is substantially reduced or absent. The ischemic cascade at a cellular level induced by reduced/absent CBF has been studied for decades, and many different pathways have been identified.

An organized stroke protocol is highly recommended to expedite evaluation. The initial evaluation of any patient is airway, breathing, circulation, and vital signs. The following neuroimaging techniques may also be used emergently: CT angiography and CT perfusion scanning, Magnetic resonance imaging (MRI), Carotid duplex scanning, Digital subtraction angiography, Lumbar puncture. Laboratory studies also involve Complete blood count (CBC), Basic chemistry panel, Coagulation studies etc. The goal of therapy in acute ischemic stroke is to preserve tissue in areas where perfusion is decreased but sufficient to avoid infarction. Recanalization strategies include recombinant tissue-type plasminogen activator. Restoring blood flow can minimize the effects of ischemia only if performed quickly. Endovascular techniques have been used in the treatment of acute ischemic stroke. Another consideration is neuroprotective agents that may be considered are Alteplase, Mechanical Thrombectomy, Blood Pressure, Antiplatelet Treatment and Antithrombotic Treatment, Statins for the treatment of the disease.

"Acute Ischemic Stroke- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

Acute Ischemic Stroke Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

Prourokinase recombinant: Tasly Pharmaceutical

Prourokinase recombinant, is an investigational drug being developed by Tasly Pharmaceutical for the treatment of Acute Ischemic Stroke. Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. It has the advantages of more potent efficacy and less adverse reactions in comparison with other thrombolytics. Advantages of thrombolytic therapy using rhPro-UK for patients with acute myocardial infarction include its reliable curative effect and high safety. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Ischemic Stroke.

• RNS60: Revalesio Corporation

RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. It activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. Currently, the drug is in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.

AVLX 144: Avilex Pharma

AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS, which targets the intracellular scaffolding protein, PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH). PSD-95 bridges the glutamate receptor subtype - the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS) via its two PDZ domains and AVLX-144 binds to both these PDZ domains simultaneously. The specific design of AVLX-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability, and enhanced neuroprotective properties. Currently, the drug is in the Phase I stage of its development for the treatment of Acute Ischemic Stroke.

Acute Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Ischemic Stroke

There are approx. 20+ key companies which are developing the therapies for Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. Phase III include, Tasly Pharmaceutical.

Phases

The report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke drugs.

Acute Ischemic Stroke Report Insights

• Acute Ischemic Stroke Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Ischemic Stroke Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Ischemic Stroke drugs?
• How many Acute Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tasly Pharmaceutical
• Revalesio Corporation
• Avilex Pharma
• GNT Pharma
• Biogen
• AptaTargets
• NC Medical Research
• Prolong Pharmaceuticals
• Saillant Therapeutics
• TargED Biopharmaceuticals

Key Products

• Prourokinase recombinant
• RNS60
• AVLX 144
• Nelonemdaz
• BIIB131
• ApTOLL
• NCS 01
• PP-007
• ST-01
• Microlyse

This product will be delivered within 1-3 business days.